Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-PALISADE phase 3 master protocol in symptomatic peripheral artery disease after lower extremity revascularization
jRCT2031260493Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of REGN7508, amrecibart, rivaroxaban and Placebo-COD Research Private Ltd in arteriosclerosis obliterans (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Time-to-first major thrombotic vascular event and Time-to-first ISTH major or clinically relevant non-major bleeding. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
REGN7508amrecibartrivaroxabanPlacebo-COD Research Private Ltd
03
Conditions
arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2031260493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260493.